News headlines about Dare Bioscience (NASDAQ:DARE) have trended somewhat positive on Wednesday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Dare Bioscience earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 44.9007084091184 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Dare Bioscience (NASDAQ:DARE) traded up $0.01 during midday trading on Wednesday, reaching $2.37. The company had a trading volume of 39,900 shares, compared to its average volume of 24,230. The company has a market cap of $14.33, a price-to-earnings ratio of -1.05 and a beta of 2.45. Dare Bioscience has a 1-year low of $2.11 and a 1-year high of $35.80.
Separately, ValuEngine upgraded Dare Bioscience from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 9th.
Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.
Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.